Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Alba Dalmases"'
Autor:
Julia Inglés-Esteve, Mònica Morales, Alba Dalmases, Ricard Garcia-Carbonell, Alba Jené-Sanz, Núria López-Bigas, Mar Iglesias, Cristina Ruiz-Herguido, Ana Rovira, Federico Rojo, Joan Albanell, Roger R Gomis, Anna Bigas, Lluís Espinosa
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e38347 (2012)
14-3-3σ is frequently lost in human breast cancers by genetic deletion or promoter methylation. We have now investigated the involvement of 14-3-3σ in the termination of NF-κB signal in mammary cells and its putative role in cancer relapse and met
Externí odkaz:
https://doaj.org/article/944020d04a674d06a7a2745816d67924
Autor:
Clara Montagut, Ana Rovira, Joan Albanell, Beatriz Bellosillo, Michael Kragh, Thomas Tuxen Poulsen, Mariona Gelabert-Baldrich, Sergi Clavé, Alba Dalmases, Élisabeth Gaye, Sílvia Menéndez, Mar Iglesias, Laura Visa, Oriol Arpí, Francisco Javier Sánchez-Martín, Aïda Sampera
Supplementary Figures and Material and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c283e805f3486b9bc952a2ff90fadb7
https://doi.org/10.1158/1535-7163.22518999.v1
https://doi.org/10.1158/1535-7163.22518999.v1
Autor:
Clara Montagut, Ana Rovira, Joan Albanell, Beatriz Bellosillo, Michael Kragh, Thomas Tuxen Poulsen, Mariona Gelabert-Baldrich, Sergi Clavé, Alba Dalmases, Élisabeth Gaye, Sílvia Menéndez, Mar Iglesias, Laura Visa, Oriol Arpí, Francisco Javier Sánchez-Martín, Aïda Sampera
Despite the clinical benefit of trastuzumab, eventually all HER2-amplified gastric cancer tumors develop drug resistance. We aimed to identify molecular mechanisms of acquired resistance to trastuzumab in gastric cancer by using well-established cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e5486c13f06d3e5057276e0a3643c9c
https://doi.org/10.1158/1535-7163.c.6542220
https://doi.org/10.1158/1535-7163.c.6542220
Autor:
Clara Montagut, Alberto Bardelli, Joan Albanell, Federica Di Nicolantonio, Ana Rovira, Gianni De Fabritiis, Joaquim Bellmunt, Alba Dalmases, Juan Sánchez, Marta Salido, Giovanni Crisafulli, Sebastijan Hobor, Giorgio Corti, Elena Gavilan, Mar Iglesias, Iria González, Sandra Misale, Mariangela Russo, Noelia Ferruz, Luca Lazzari, Israel Cañadas, Alejandro Martínez, Giulia Siravegna, Beatriz Bellosillo, Sabrina Arena
Purpose: Patients with colorectal cancer who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment, the molecular landscape of resistant tumors must be ascer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a99b29e080404b8cca8b9c0e5f7a15a
https://doi.org/10.1158/1078-0432.c.6524322.v1
https://doi.org/10.1158/1078-0432.c.6524322.v1
Autor:
Clara Montagut, Alberto Bardelli, Joan Albanell, Federica Di Nicolantonio, Ana Rovira, Gianni De Fabritiis, Joaquim Bellmunt, Alba Dalmases, Juan Sánchez, Marta Salido, Giovanni Crisafulli, Sebastijan Hobor, Giorgio Corti, Elena Gavilan, Mar Iglesias, Iria González, Sandra Misale, Mariangela Russo, Noelia Ferruz, Luca Lazzari, Israel Cañadas, Alejandro Martínez, Giulia Siravegna, Beatriz Bellosillo, Sabrina Arena
Supplementary Table S3. Prevalence of EGFR mutations in resistant cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04c97e2237e2738caf155e1202605f49
https://doi.org/10.1158/1078-0432.22459836.v1
https://doi.org/10.1158/1078-0432.22459836.v1
Autor:
Clara Montagut, Alberto Bardelli, Josep Tabernero, Joan Albanell, Ana Rovira, Michael Kragh, Christopher Stroh, Mar Iglesias, Ivan David Horak, Oriol Arpí, Laura Visa, Klaus Koefoed, Sabrina Arena, Giulia Siravegna, Guillem Argilés, Alejandro Martinez, Joana Vidal, Israel Cañadas, Alba Dalmases, Mariona Gelabert-Baldrich, Beatriz Bellosillo, Francisco J. Sánchez-Martín
Purpose: Approved anti-EGFR antibodies cetuximab and panitumumab provide significant clinical benefit in patients with metastatic colorectal cancer (MCRC). However, patients ultimately develop disease progression, often driven by acquisition of mutat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0447248cfc43c1609997d7086effd715
https://doi.org/10.1158/1078-0432.c.6522941.v1
https://doi.org/10.1158/1078-0432.c.6522941.v1
Autor:
Clara Montagut, Alberto Bardelli, Joan Albanell, Federica Di Nicolantonio, Ana Rovira, Gianni De Fabritiis, Joaquim Bellmunt, Alba Dalmases, Juan Sánchez, Marta Salido, Giovanni Crisafulli, Sebastijan Hobor, Giorgio Corti, Elena Gavilan, Mar Iglesias, Iria González, Sandra Misale, Mariangela Russo, Noelia Ferruz, Luca Lazzari, Israel Cañadas, Alejandro Martínez, Giulia Siravegna, Beatriz Bellosillo, Sabrina Arena
The file contains Supplementary Table and Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70d74a0a5005eecd03b698bf4cc0b27f
https://doi.org/10.1158/1078-0432.22459833
https://doi.org/10.1158/1078-0432.22459833
Autor:
Clara Montagut, Alberto Bardelli, Joan Albanell, Federica Di Nicolantonio, Ana Rovira, Gianni De Fabritiis, Joaquim Bellmunt, Alba Dalmases, Juan Sánchez, Marta Salido, Giovanni Crisafulli, Sebastijan Hobor, Giorgio Corti, Elena Gavilan, Mar Iglesias, Iria González, Sandra Misale, Mariangela Russo, Noelia Ferruz, Luca Lazzari, Israel Cañadas, Alejandro Martínez, Giulia Siravegna, Beatriz Bellosillo, Sabrina Arena
Supplementary Figure S3. Nucleotide sequence of the EGFR gene in cetuximab resistant cell lines.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b129d07998c81aa0431435a5d61063
https://doi.org/10.1158/1078-0432.22459845
https://doi.org/10.1158/1078-0432.22459845
Autor:
Clara Montagut, Alberto Bardelli, Josep Tabernero, Joan Albanell, Ana Rovira, Michael Kragh, Christopher Stroh, Mar Iglesias, Ivan David Horak, Oriol Arpí, Laura Visa, Klaus Koefoed, Sabrina Arena, Giulia Siravegna, Guillem Argilés, Alejandro Martinez, Joana Vidal, Israel Cañadas, Alba Dalmases, Mariona Gelabert-Baldrich, Beatriz Bellosillo, Francisco J. Sánchez-Martín
Figure S1: EGFR mutants binding to CTX, Sym004, PNM Figure S2: Clonogenic assay in EGFR mutants with CTX, Sym004, PNM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e8a45ab8be055356949c839d58e95d
https://doi.org/10.1158/1078-0432.22455152.v1
https://doi.org/10.1158/1078-0432.22455152.v1
Autor:
Joan Gibert, M. Hardy-Werbin, Pedro P. Rocha, Sergi Clavé, Raquel Longarón, Edurne Arriola, Marta Salido, Imane Chaib, Álvaro Taus, Alba Dalmases, Teresa Moran, Gabriel Piquer, Beatriz Bellosillo, Enric Carcereny
Publikováno v:
Lung Cancer. 140:42-45
KRAS mutations are one of the most prevalent alterations in non-small cell lung cancer. However, patients with this driver alteration present heterogeneous clinical outcomes. In this study, we have explored the potential clinical impact of coexisting